Medtronic Elevates 2027 Projections Amid Rising Heart Device Demand

Medtronic has adjusted its fiscal 2027 forecasts upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The company announced that it now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous prediction of 6.75% to 7.25%.

Strategic Investments and Collaborations

In a strategic move to bolster its portfolio, Medtronic has committed $80 million to invest in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device outside the United States. CEO Geoff Martha emphasized the complementary nature of Cornerstone's Sentire device to Medtronic's Hugo system, particularly in emerging markets where soft tissue robotic surgery has less than 1% penetration.

Financial Outlook and Performance

Alongside its revised revenue growth projections, Medtronic has adjusted the lower end of its fiscal 2027 adjusted per share profit forecast from $5.90 to $5.94, maintaining the upper end at $6. The company's financial results exceeded expectations, with a reported adjusted quarterly profit of $1.45 per share on revenues of $9.76 billion, surpassing the estimates of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Medtronic's cardiovascular segment experienced a significant boost, with quarterly sales climbing 19.5% to $3.93 billion. This surge was largely driven by the company's pulsed field ablation portfolio, which saw an 88% increase, underscoring the growing demand for solutions to treat irregular heart rhythms.

Market Confidence and Future Prospects

CEO Geoff Martha expressed confidence in the company's performance, highlighting the broad contributions from various business segments and new growth platforms as key factors. Medtronic's Chief Financial Officer Thierry Pieton noted that the company received tariff refunds that nearly offset duties paid during the quarter, though future refunds have not been factored into the current outlook.

Martha also pointed to a steady pace of mergers and acquisitions, with a focus on high-growth segments within the medtech industry. Medtronic's strategic investments aim to capture large patient pools and significant market segments, aligning with its growth objectives.